PMD16 - HEALTH ECONOMIC EVALUATION OF AN ULTRATHIN, BIORESORBABLE POLYMER SIROLIMUS-ELUTING CORONARY STENT COMPARED TO A THIN, DURABLE POLYMER EVEROLIMUS-ELUTING STENT

•The BIOFLOW V trial compared an ultrathin, bioresorbable polymer sirolimus-eluting stent to a thin, durable polymer everolimus-eluting stent. The ultrathin stent had a significantly lower rate of peri-procedural myocardial infarction.•This analysis simulated mortality and cost impact of that difference from a U.S. health system perspective over 12 months.•The difference was estimated to translate into cost reductions of $124 per patient in 2018 US$, of which 93% accrued to the initial admission.•The lower rate of ppMI translates into a gain of 17 quality-adjusted life-years (QALY) per one million patients